TVRD Stock Summary and Trading Ideas (Tvardi Therapeutics | NASDAQ:TVRD)

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Tvardi Therapeutics trades on the NASDAQ stock market under the symbol TVRD.

As of July 7, 2026, TVRD stock price climbed to $3.10 with 69,773,480 million shares trading.

TVRD has a beta of 0.91, meaning it tends to be less sensitive to market movements. TVRD has a correlation of 0.00 to the broad based SPY ETF.

TVRD has a market cap of $29.07 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that TVRD belongs to (by Net Assets): VTI, VXF, VTWO, VTWV, VTWG.

TVRD has underperformed the market in the last year with a return of -85.6%, while the SPY ETF gained +21.7%. In the last 3 month period, TVRD fell short of the market, returning +8.8%, while SPY returned +13.7%. However, in the most recent 2 weeks TVRD has outperformed the stock market by returning +28.1%, while SPY returned +1.9%.

TVRD support price is $1.86 and resistance is $2.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TVRD shares will trade within this expected range on the day.